source
- UniQure to submit UK marketing application for Huntington's gene therapy AMT-130UniQure announced it will file a marketing application in the United Kingdom later this year for its gene therapy AMT-130 aimed at Huntington's disease. The filing follows a positive meeting with…
- Avalyn Pharma raises $300M in IPO to fund inhalable lung-fibrosis drugsAvalyn Pharma completed a $300 million initial public offering, pricing 16.7 million shares at $18 each and exceeding its original $200 million target. The proceeds will be used to develop inhalab…